Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin Commences Japan PII Study of NHE3 Inhibitor for Hyperphosphatemia
February 7, 2019
- JCR, Teijin Launch Japan PI/PII of Regenerative Medicine Product for Cerebral Infarction
February 7, 2019
- Kyowa Kirin to Delay 100 Billion Yen Profit Goal, Plans 1st Voluntary Redundancy Program
February 6, 2019
- Kyowa Kirin Sales Slip 1.9% in 2018, but Profit Up on One-Off Factors
February 6, 2019
- Kyowa Kirin to Market Hisamitsu’s Transdermal Parkinson’s Drug
February 6, 2019
- Taiho Licenses Novel EGFR-TKI to US Firm Outside Japan
February 6, 2019
- Q3 Earnings Rundown: Eisai, Takeda, Ono, and More
February 5, 2019
- Ichiro Watanabe to Head Up Teijin Pharma
February 5, 2019
- Oropharyngeal Candidiasis Drug Oravi Now Available in Japan
February 4, 2019
- Takeda Drops US Filing for Ninlaro Label Expansion, Plans Resubmission with OS Data
February 4, 2019
- Keytruda Beats Opdivo in Q4 Global Sales including Asia
February 4, 2019
- Sawai and 7 Other Generic Makers Seeking Lyrica Patent Invalidity
February 4, 2019
- Chugai Plays It Safe with New 3-Year Plan on Consecutive Re-Pricing, Eyes 7-9% Annual EPS Growth
February 1, 2019
- Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
February 1, 2019
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
- Daiichi Sankyo Selling Takatsuki Plant to Taiyo for 37.6 Billion Yen
February 1, 2019
- Ono Grabs Asian Rights to Repare’s Pol-theta Inhibitor
February 1, 2019
- JT Files Topical JAK Inhibitor in Japan for Atopic Dermatitis
February 1, 2019
- FDA Nixes Sunovion’s Parkinson’s Drug, but Requires No New Studies
February 1, 2019
- Fycompa Filed for Monotherapy, Pediatric Use in Japan: Eisai
January 31, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…